- •
The development of new drugs to treat maternal and fetal conditions can be improved using approaches that are succeeding in other marginalized therapeutic areas.
- •
Improved information about the risks and benefits of interventions during pregnancy is needed to facilitate study design and review by ethics boards, regulators, funders, and potential participants of studies.
- •
It is important to ensure that the design and conduct of in vitro, ex vivo, and clinical studies are compatible with the needs of
Challenges in Designing Clinical Trials to Test New Drugs in the Pregnant Woman and Fetus
Section snippets
Key points
Challenges
Profound changes in maternal physiology fundamentally alter pharmacokinetics (PK) and pharmacodynamics, often in an unpredictable fashion. There are 3 discrete and intimately dependent units comprising the mother, the fetus, and the placenta. The placenta, once thought to be a passive filter between the maternal and fetal compartments, is in fact a highly complex organ rich in transporters. The human placenta remains relatively understudied, particularly in early healthy pregnancy. Comparative
Funding
Globally, the allocation of resources to the development of new drugs is controversial, and pharmaceutical companies currently have many reasons to avoid investing in pregnancy research.24, 41 As noted in the legal section of this review, disadvantage risks are highly visible (legal liability, and so forth) and compare unfavorably to any potential financial benefits. Information about the burden of disease is available but needs to be presented more effectively to decision-makers in companies,
Ethics
The ethics of research involving pregnant women may seem straightforward. For example, a 1994 report by the US Institute of Medicine recommended that “pregnant women be presumed to be eligible for participation in clinical studies.”45 International ethical guidance also promotes appropriate research that recruits pregnant women (CIOMS 2016; https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf). On the other hand, a systematic review of ethical issues that arise during
Fetus and neonate
The central, and unique, problem for research in pregnancy is the need to account for the interests of 2 (or more) participants: the mother and her offspring. The balance between maternal and fetal interests is difficult to consider, both emotionally and cognitively, unless you have experienced it as a parent or a caregiver. However, families and clinicians do this regularly in clinical practice. Many people approach the situation with a natural inclination to avoid harm to a fetus. However, in
Solutions
Activities in single programs and for the community are summarized and compared in Fig. 1. These activities cannot be done in isolation. A systems approach is needed to address “all the layers of the onion,” which is illustrated in Fig. 2.
Summary
This review has addressed the challenges that arise when testing new and existing drugs that could be used during pregnancy. The authors have emphasized a multileveled approach needed to overcome these challenges.
Individual drug development programs need to gather a body of scientific and clinical information with drug development in mind. Drug development benefits from the structure provided by regulatory pathways, even if a regulatory filing is not an objective of a programme of research.
References (69)
Techniques to study human placental transport
Adv Drug Deliv Rev
(1999)Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction
Placenta
(2017)Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies
J Reprod Immunol
(2017)- et al.
Preliminary interlaboratory comparison of the ex vivo dual human placental perfusion system
Reprod Toxicol
(2010) - et al.
Integration and validation of the ex vivo human placenta perfusion model
J Pharmacol Toxicol Methods
(2017) - et al.
An international network (PlaNet) to evaluate a human placental testing platform for chemicals safety testing in pregnancy
Reprod Toxicol
(2016) - et al.
Biomedical research: increasing value, reducing waste
Lancet
(2014) - et al.
Adverse drug reactions in high-risk pregnant women: a prospective study
Saudi Pharm J
(2017) - et al.
Pneumococcal conjugate vaccines as maternal and infant immunogens: challenges of maternal recruitment
Vaccine
(2003) - et al.
Optimizing participation of pregnant women in clinical trials: factors influencing decisions about participation in medication and vaccine trials
J Obstet Gynaecol Can
(2016)
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach
Lancet Infect Dis
Enrollment of neonates in more than one clinical trial
Clin Ther
Chronic pulmonary insufficiency of prematurity: developing optimal endpoints for drug development
J Pediatr
Accelerating the paradigm shift toward inclusion of pregnant women in drug research: ethical and regulatory considerations
Semin Perinatol
Drug development for neglected diseases: a deficient market and a public-health policy failure
Lancet
Improving the pipeline for developing and testing pharmacological treatments in pregnancy
PLoS Med
ACOG committee opinion no. 646: ethical considerations for including women as research participants
Obstet Gynecol
Market failure and the poverty of new drugs in maternal health
PLoS Med
Clinical research enrolling pregnant women: a workshop summary
J Womens Health (Larchmt)
Developing new pharmaceutical treatments for obstetric conditions
Designing drug trials: considerations for pregnant women
Clin Infect Dis
Drug development and obstetrics: where are we right now?
J Matern Fetal Neonatal Med
Animal models to study placental development and function throughout normal and dysfunctional human pregnancy
Semin Reprod Med
Transplacental nutrient transport mechanisms of intrauterine growth restriction in rodent models and humans
Front Physiol
What evidence do we need for biomarker qualification?
Sci Transl Med
Believe it or not: how much can we rely on published data on potential drug targets?
Nat Rev Drug Discov
Pregnant women: scientific and ethical considerations for inclusion in clinical trials guidance for industry
An ethically justified framework for clinical investigation to benefit pregnant and fetal patients
Am J Bioeth
Mitigating risk in academic preclinical drug discovery
Nat Rev Drug Discov
Drug dosing in pregnant women: challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations
CPT Pharmacometrics Syst Pharmacol
Industry perspective of drug development for pregnant/breastfeeding women
Clin Pharmacol Ther
Research with pregnant women: new insights on legal decision-making
Hastings Cent Rep
Ethical framework for observational studies of medicinal drug exposure in pregnancy
Teratology
Development of the liverpool adverse drug reaction avoidability assessment tool
PLoS One
Cited by (6)
Engineered tissues and strategies to overcome challenges in drug development
2020, Advanced Drug Delivery ReviewsCitation Excerpt :However, it took decades of observational human population studies to support and propose a clinical trial to confirm the therapeutic benefit of folic acid supplementation [87], and there are likely many more nutrient or environmental factors that influence NTDs and other developmental disorders. Overall, there is a need for new preclinical models that capture the underlying biological processes of human development [88]. In addition to the screening for teratogenic effects of pharmacologic compounds, advancements in models of human development are needed that can provide a discovery platform for identifying potential drugs or drug-like compounds that can potentially mitigate developmental disorders.
Research Networks and Accelerated Research Pathways for Perinatal Health
2023, COVID-19 and PerinatologyPredicting completion of clinical trials in pregnant women: Cox proportional hazard and neural network models
2022, Clinical and Translational ScienceDevelopment of standard definitions and grading for Maternal and Fetal Adverse Event Terminology
2022, Prenatal DiagnosisAnti-Infective Dosing in Special Populations: Pregnancy
2021, Clinical Pharmacology and TherapeuticsResearch in pregnant subjects: Increasingly important, but challenging
2020, Ochsner Journal
Disclosure Statement: No disclosures.